A Pilot Study Comparing Two Different Sirolimus-based Transition Regimens in African-American Renal Transplant Recipients
概览
- 阶段
- 不适用
- 干预措施
- rapamune, mycophenolate mofetil and steroid
- 疾病 / 适应症
- Absence; Kidney
- 发起方
- Medical University of South Carolina
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- Effectiveness and Safety of a Particular Drug Regimen to Prevent Kidney Rejection
- 状态
- 已完成
- 最后更新
- 10年前
概览
简要总结
This study's focus is to compare the level effectiveness and safety of regimens involving Sirolimus, Cellcept and steroid to Prograf, Sirolimus and steroid in African-American recipients of kidney transplants.
详细描述
A major concern in transplantation is finding a successful regimen of medications to lower the potential for the body to reject the newly transplanted organ. The regimens in kidney transplantation include tacrolimus, sirolimus, mycophenolate mofetil and steroids. This study will compare the effectiveness and safety of a regimen including Sirolimus, Prograf, and steroids compared to a regimen including Sirolimus, Cellcept and steroids. These regimens have already been researched in the Caucasian population, and both drug regimens are FDA approved. This study's focus is on the effectiveness and safety of these regimens in African-Americans.
研究者
入排标准
入选标准
- •At least 18 years of age and able to give informed consent
- •African-American ethnicity
- •Received a first or second non-ECD cadaveric or living donor renal transplant
- •Transplant occurred during the past 6 to 24 weeks
- •Patient has stable graft function, defined as no change of greater than 30% of baseline serum creatinine during the past month and no acute rejection in the past 6 weeks
- •Estimated GFR using the modified MDRD equation of at least 40 mL/min10 at time of enrollment into the study
- •Currently receiving tacrolimus, mycophenolate mofetil (at least 1 gm per day), and corticosteroids as their immunosuppression regimen.
排除标准
- •Biopsy proven acute rejection episode that occurred within the past 6 weeks
- •Malignancy within the past 3 years, except for non-melanoma skin cancer
- •Any known intolerances to current immunosuppressant regimen necessitating withdrawal of the offending agent
- •Currently enrolled in an investigational trial
- •Woman of child bearing potential not utilizing an effective form of birth control
- •Patients with uncontrolled dyslipidemia, defined at serum fasting LDL \>200 mg/dL or serum fasting triglycerides \>500 mg/dL.
- •Patients with a spot urine protein to creatinine ratio of \> 800 mg of protein per gram of creatinine.
- •WBC \< 3,000 cells/mm3
- •Platelets \< 100,000 cells/mm3
研究组 & 干预措施
Tacrolimus Withdrawal Arm
At the time of transition patients randomized into this arm of the study will receive loading doses of sirolimus for two days and then 5mg PO daily. Twenty-four hour troughs will be checked per the schedule to ensure and monitor the therapeutic concentrations of 8-12ng/ml. Patients randomized into this arm of the study will continue their current dosing regimen and frequency of mycophenolate mofetil. Serum trough level monitoring of mycophenolic acid will not be performed unless clinically warranted per standard of care and dosage adjustments from such levels will be made only with consent of the study primary investigator.
干预措施: rapamune, mycophenolate mofetil and steroid
Tacrolimus Minimization Arm
Tacrolimus dosing is based on 12-hour whole blood trough concentrations. Target blood concentration is 2-5 ng/ml. At the time of transition patients randomized into this arm of the study will receive loading doses of Sirolimus for two days and then 5mg PO daily. Twenty-four hour troughs will be checked per the schedule to ensure and monitor the therapeutic concentrations of 8-12ng/ml.
干预措施: tacrolimus, sirolimus and steroid
结局指标
主要结局
Effectiveness and Safety of a Particular Drug Regimen to Prevent Kidney Rejection
时间窗: 12 months
Number of Participants with Kidney Rejections